MT110-101: Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer

Sponsor

Amgen Research (Munich) GmbH (Industry)

Overall Status

Completed

CT.gov ID

NCT00635596

Collaborator

(none)

Enrollment

Locations

Arm

Duration (Months)

16.3

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This phase I dose escalation study is intended to define the safety, tolerability and maximal tolerable dose (MTD) of MT110 in patients with advanced solid tumors.

Condition or Disease	Intervention/Treatment	Phase
Solid Tumors	Biological: MT110	Phase 1

Detailed Description

MT110 is a bispecific (anti-EpCAM x anti-CD3) T-cell engager (BiTE) designed to link EpCAM (epithelial cell adhesion molecule) expressing cells and T-cells resulting in T-cell activation and a cytotoxic T-cell response against EpCAM+ cells. In vitro and ex-vivo data indicate that EpCAM+ tumor cell lines are sensitive to MT110 mediated cytotoxicity. Furthermore, data from in-vivo experiments with both MT110 and a mouse surrogate molecule (muS110) have confirmed the activity of these molecules in inhibiting the formation of metastases but also against established tumors. In vitro and ex-vivo data suggest that a prolonged presence of the drug in target tissues may result in significant T-cell recruitment, activation and expansion to/in target tissues, potentially resulting in substantial anti-tumor activity in man.

Study Design

Study Type:

Interventional

Actual Enrollment :

65 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

An Open-label, Multi-center Dose Escalation Phase I Study to Investigate the Safety and Tolerability of a Continuous Infusion of the Bispecific T-cell Engager (BiTE) MT110 in Locally Advanced, Recurrent or Metastatic Solid Tumors Which Commonly Express EpCAM and Are Not Amenable to Curative Treatment

Study Start Date :

Mar 1, 2008

Actual Primary Completion Date :

Jan 1, 2014

Actual Study Completion Date :

Jan 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Experimental: I	Biological: MT110 MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses Other Names: bispecific T-cell engager (BiTE)

Arm

Intervention/Treatment

Experimental: I

Biological: MT110

MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses

Other Names:

bispecific T-cell engager (BiTE)

Outcome Measures

Primary Outcome Measures

Overall frequency and intensity of adverse events (AEs) (clinical symptoms, laboratory abnormalities, serious adverse events [SAEs] and dose-limiting toxicities) [one or more treatment cycles]

Secondary Outcome Measures

Pharmacokinetics of MT110; T-cell counts, kinetics, and activation status; Serum cytokine concentrations; Immunogenicity; Anti-tumor activity; Other progressive disease (PD) parameters [one or more treatment cycles]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Locally advanced, recurrent or metastatic solid tumors known to widely express EpCAM and proven histology of the following entities:

Adenocarcinoma of the lung
Small cell lung cancer (SCLC)
Gastric cancer or adenocarcinoma of gastro-esophageal junction
Colorectal cancer (CRC)
Hormone-refractory prostate cancer (HRPC)
Breast cancer
Ovarian cancer

Patients must not be amenable to curative therapy. Patients should have exhausted or declined standard therapeutic options and previous therapies should have included at least one course of chemotherapy.

Non-measurable disease or at least one measurable tumor lesion as per RECIST criteria
Age >/= 18 years
ECOG performance status </= 2
Life expectancy of at least 3 months
Must have recovered from the acute reversible effects of previous anti-cancer chemotherapy, endocrine therapy, immunotherapy, radiotherapy or surgery.

This generally means at least 4 weeks since major surgery, radical radiotherapy or myelosuppressive chemotherapy (6 weeks for nitrosoureas or mitomycin C).
At least 4-5 half-lives (t1/2) must have elapsed since treatment with an investigational agent.
At least 4 weeks since any hormonal therapy (except LHRH agonists for patients with HRPC) prior to initiating MT110 treatment.

Ability to understand the patient information and informed consent form
Signed and dated written informed consent

Exclusion Criteria:

Evidence of central nervous system (CNS) metastases on baseline computer tomography (CT) or magnetic resonance imaging (MRI) scan (mandatory for all patients), current or past relevant history of other CNS pathology (except migraine, headache and minor incidental findings in the MRI without any clinical manifestation within the last five years). All minor incidental findings should be discussed with the Sponsor's Medical Monitor).
Neutrophil count < 1,500/mm3 (= 1.5 x 10^9/l)
Platelet count < 100,000/mm3 (= 100 x 10^9/l)
White blood cells (WBC) < 3 x10^9/l
Hemoglobin < 9.0 g/dl
Abnormal renal or hepatic function as defined below:

Alkaline phosphatase (AP)>/= 2.5 x upper limit of normal (ULN) and/or aspartate aminotransferase (AST, SGOT), alanin aminotransferase (ALT, SGPT) >/= 2.0 x ULN or AP, AST and/or ALT >/= 3 x ULN in case of liver metastases; γ-glutamyl transpeptidase (GGT) >/= 5.0 x ULN
Total bilirubin >/= 1.5 x ULN
Creatinine clearance < 50 ml/min calculated by the Cockroft-Gault formula or MDRD (modification of diet in renal disease)
Lipase/amylase > 1.5 x ULN
D-dimer >/= 10 x ULN
Antithrombin activity < 70%
International normalized ratio (INR) > ULN
Partial thromboplastin time (PTT) > ULN

Oxygen (O2) saturation of < 92% (under room air condition)
Any concurrent anti-neoplastic therapy with the exception of radiotherapy for palliation of symptoms after agreement by the Sponsor's Medical Monitor. No radiation is allowed for defined measurable lesions according to RECIST. Patients with HRPC who have received LHRH-agonist therapy for >1 month, should continue agonist therapy.
Any concurrent disease, medical or social condition that could affect compliance with the protocol or interpretation of results as judged by the investigator. In particular, patients with the following conditions are not allowed to enter the study:

Autoimmune and inflammatory diseases including vasculitis, rheumatoid arthritis, systemic lupus erythematosus (SLE), multiple sclerosis and similar conditions
Active infection or known bacteremia
Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus
Severe dyspnea or pulmonary dysfunction or need for continuous supportive oxygen inhalation
Insufficient cardiac function defined as NYHA (New York Heart Association) Grade 3 or 4
History of acute or chronic pancreatitis

Chronic systemic corticosteroid therapy longer than 2 months or any other immunosuppressive therapies or stem-cell transplantation.
Presence of human anti-murine antibodies (HAMA) or known hypersensitivity to immunoglobulins or to other ingredients of the infusion solution.
Pregnant, nursing women or women of childbearing potential who are not willing to use effective forms of contraception during participation in the study and at least three months thereafter.
Male patients with partners of child-bearing potential who are not willing to use effective contraception during the trial and for at least three months thereafter, unless surgically sterile.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University Hospital Freiburg Gynecological Clinic	Freiburg	Baden-Württemberg	Germany	79106
2	University Hospital Hamburg-Eppendorf	Hamburg		Germany	20246
3	Hospital Kassel	Kassel		Germany	34125
4	University Hospital Würzburg	Würzburg		Germany	97080